Professor Glenn Marshall has been Head of the Molecular Carcinogenesis Program at Children’s Cancer Institute since 1995.
His primary preclinical research interests include investigating the mechanisms by which normal embryonal cells become cancerous, and improving the effectiveness of non-cytotoxic anti-cancer therapy in child cancer. Glenn has a longstanding clinical and translational research focus on relapse detection by Minimal Residual Disease (MRD) testing in leukaemia, and the therapy of high-risk or relapsed leukaemia. He was instrumental in the genesis of the current national study of children with acute lymphoblastic leukaemia (ALL) conducted by the Molecular Diagnostics Program, which has applied MRD testing to individualise therapy in ALL. With colleagues at the Children’s Hospital Westmead, John Hunter Children’s Hospital and Ronald McDonald Learning Program, he helped initiate the Learning Pathways Project for Children with Cancer in 2007.
In addition to his research activities, Glenn is a full-time paediatric haematologist and oncologist, Director of the Centre for Children's Cancer and Blood Disorders and Senior Staff Specialist at Kids Cancer Centre at Sydney Children's Hospital, Randwick. He is also a conjoint Professor, School of Women and Children’s Health, Faculty of Medicine at UNSW. Glenn has published more than 140 original research articles on various biological and clinical aspects of child cancer. In 2011, he was appointed Head of Translational Research at Children’s Cancer Institute.
With colleagues Professors Haber and Norris, he received the Premier’s Award for Excellence in Translational Cancer Research and the NHMRC “Ten of the Best” award in 2012. He was profiled in The Lancet on 25 March 2013 as a successful clinician-scientist. He was awarded an Order of Australia (AM) in 2014 for significant service to medicine in the field of paediatric oncology.